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ABSTRACT
In the era towards precision medicine, we here present the individual specific autoantibody signatures
of 193 healthy individuals. The self-reactive IgG signatures are stable over time in a way that each indi-
vidual profile is recognized in longitudinal sampling. The IgG autoantibody reactivity towards an anti-
gen array comprising 335 protein fragments, representing 204 human proteins with potential
relevance to autoimmune disorders, was measured in longitudinal plasma samples from 193 healthy
individuals. This analysis resulted in unique autoantibody barcodes for each individual that were main-
tained over one year’s time. The reactivity profiles, or signatures, are person specific in regards to the
number of reactivities and antigen specificity. Two independent data sets were consistent in that each
healthy individual displayed reactivity towards 0–16 antigens, with a median of six. Subsequently, four
selected individuals were profiled on in-house produced high-density protein arrays containing 23,000
protein fragments representing 14,000 unique protein coding genes. Based on a unique, broad and
deep longitudinal profiling of autoantibody reactivities, our results demonstrate a unique autoreactive
profile in each analyzed healthy individual. The need and interest for broad-ranged and high-reso-
lution molecular profiling of healthy individuals is rising. We have here generated and assessed an ini-
tial perspective on the global distribution of the self-reactive IgG repertoire in healthy individuals, by
investigating 193 well-characterized healthy individuals.
HIGHLIGHTS
 A unique longitudinal profiling of autoantibody repertoires in healthy individuals
 Autoantibody profiles are highly individual and stable over time
 All individuals display IgG binding to human protein fragments
 The specificity of disease associated autoantigens needs to be thoroughly characterized
 The identification of a small set of highly reactive autoantigens
 Importance of stringent antigen and sample specific cut-offs for defining reactivity
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Although it is commonly believed that the population of
immature B cells is purged of cells bearing self-reactive B
cell receptors, it is also well established that all individuals
display a wide variety of antibodies in their periphery that
could react to self and non-self-antigens regardless of exter-
nal stimuli [1]. Indeed, the term “natural autoantibodies”
was first described by Boyden in the early 1960s referring to
an autoreactive response in sera of a healthy individual [2].
In 1988, Francoeur published the term “individual specific
antibodies” to describe the self-reacting repertoire of anti-
bodies in healthy individuals [3].
Since then, there have been limited possibilities to per-
form broad and deep profiling of the global autoantibody
repertoires, with a shortage in efforts to characterize the dis-
tribution of autoantibody targets within diseases with known
or speculated autoimmune components. This has also
affected the possibilities for screening for novel autoanti-
gens. Indeed, several disease-associated autoantigen candi-
dates could possibly, or even likely, be part of the global
autoantibody repertoires identified among healthy individu-
als. We therefore consider that it is of great importance to
establish and explore the general specificities of IgG reper-
toires, not at least within healthy individuals. There are
three main requirements to perform this: i) access to a
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proteome-wide range representation of human proteins; ii)
multiplexed assay formats enabling the analysis of large
numbers of potential autoantigens as well as large numbers
of samples in parallel; iii) well-characterized and carefully
selected longitudinal sample materials of a decent size.
The Human Protein Atlas (HPA, www.proteinatlas.org)
has for a period of 15 years been devoted to the production
of E. coli-expressed protein fragments for immunization
into rabbits in order to generate polyclonal antibodies that
can be used for the characterization of protein expression
and localization of basically all human proteins in tissues
and cells [4,5]. Currently, more than 42,000 unique and
mass spectrometry verified protein fragments of in average
80 amino acids have been produced. We have within HPA
developed and utilized various planar and bead-based pro-
tein microarray formats for the initial validation of antibody
specificity and for the profiling of autoantibody reper-
toires [6–12].
The access to the massive library of protein fragments
within HPA, combined with the development of novel
standardized array formats, has now enabled proteome-wide
screenings for novel autoantigen associations. We have here
utilized a custom designed antigen bead array for the paral-
lel analysis of a total of 859 unique plasma samples from
193 healthy individuals focusing on a panel of 335 protein
fragments representing 204 unique proteins. We have also
subsequently analyzed four samples on a planar array with
23,000 protein fragments representing 14,000 unique protein
coding genes.
All individuals profiled within this study were enrolled in
two separate initiatives for longitudinal sampling of healthy
individuals, one in Sweden (Swedish SCAPIS SciLifeLab
Wellness Profiling (S3WP) project) and one in Finland
(Digital Health Revolution (DHR) program at Institute for
Molecular Medicine Finland, FIMM, HiLIFE, University of
Helsinki). Both studies enrolled around 100 participants that
completed clinical phenotyping, lifestyle questionnaires and
repeated sampling of blood, urine and stool. These samples
have hitherto been deeply analysed in regards to clinical
chemistry, genomics, proteomics, metabolomics, and gut
microbiomics.
With this unique and large screening of well character-
ized healthy individuals, we have generated a first perspec-
tive on the self-reactive IgG repertoire with molecular
resolution. We show that each individual displays a personal
set of IgGs reactive to human proteins, and this profile is
stable across 4–5 samplings over one year time. With this
we want to further broaden the knowledge about natural
occurring IgG autoantibodies and their implication for
health and disease.
Materials and methods
Ethical permit and participant consent
Both the Swedish SCAPIS SciLifeLab Wellness Profiling
(S3WP) project and the Digital Health Revolution (DHR)
study were conducted according to the guidelines of the
Declaration of Helsinki. The S3WP and DHR research
protocols were approved by the coordinating ethics commit-
tee of the Ethical Review Board of Gothenburg, Sweden
(DNR 407-15) and by the HUS Hospital District (Helsinki,
Finland) (51/13/03/00/15), respectively. All participants pro-
vided a written informed consent.
S3 study population
The S3WP study is an observational study with the aim to
collect longitudinal data in a community-based cohort. A
total of 101 subjects were recruited from the ongoing
Swedish Cardio Pulmonary bioImage Study (SCAPIS),
which includes randomly selected subjects aged 50–65 years
from the general Swedish population. Examinations in
SCAPIS included imaging to assess coronary and carotid
atherosclerosis, clinical chemistry, anthropometry, and life-
style questionnaires, as previously described [13]. Thus, the
subjects were extensively phenotyped before entering the
S3WP study. In SCAPIS, no exclusion criteria were applied
except the inability to understand written and spoken
Swedish for informed consent. In the S3WP study, subjects
were excluded if they had clinically significant cardiovascu-
lar disease, diabetes, or medication for hypertension or
hyperlipidemia. At four occasions during one year, subjects
were examined and sampled. Subjects underwent identical
examinations at each visit, including measurements of body
weight, waist and hip circumference, body fat using bioim-
pedance (Tanita MC-780MA), and blood pressure. A selec-
tion of questions from the initial SCAPIS questionnaire was
repeated at each visit to note any potential changes in health
and life-style factors between each visit such as infections,
disease, medication, perceived health, and exercise level.
Each visit also included collection of blood, urine and stool
for subsequent clinical chemistry and omics analyses. From
visit 2 and onward, subjects were wearing accelerometers
(Polar A360) to measure physical activity. For more infor-
mation on the participants, see Supplementary Table 1.
DHR study population
The DHR study is a pilot for the next-generation personal-
ized health research by integrating longitudinal multi-omics
profiling, digital monitoring and personal data. The study
was conducted at the Institute for Molecular Medicine
Finland (FIMM, HiLIFE, University of Helsinki, Finland). A
total of 107 subjects (aged 25–59) from the clientele of a
private occupational health care service provider were
recruited and 87 out of them completed the study with sam-
ples given at five visits. Although none of the participants
had any previously diagnosed serious diseases, individuals
with elevated risk factors for chronic diseases were still
included. Over a 16-month period, the participants donated
blood, urine, saliva, and stool samples at five different occa-
sions. Anthropometric and physiological measurements,
questionnaire, fitness test, quantified self-tracking, and food
purchasing data were systematically collected. Clinical chem-
istry, genomics, proteomics, metabolomics, and gut micro-
biomics analyses were performed. Key actionable data were
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interpreted and returned to participants in real-time via a
personal health account and web-based tools starting from
the second study visit. These data were the basis for tailored
health and wellness advices and coaching provided by a per-
sonal trainer from the third study visit forward. For more
information on the participants, see Supplementary Table 1.
Sampling and storage of plasma
In both S3WP and DHR, all subjects were fasting overnight,
for at least 8 hours, before sampling. Blood samples were
drawn in EDTA tubes using standard operating procedures.
All samples were stored at 80 C until use.
Selection of antigens and creation of bead array
A collection of 335 antigens, representing sequence unique
regions from 204 protein coding genes, were selected based
on potential relevance to autoimmune disorders. Antigens
were identified from literature or from previous internal
studies (see Supplementary Table 2 for complete collection
of the covered protein coding genes and corresponding
references). The antigens consisted of protein fragments
(20–163 amino acids, with a median of 79) produced within
the Human Protein Atlas project, www.proteinatlas.org [4].
All fragments were expressed in Escherichia coli with a six
histidine and albumin binding protein tag (His6ABP). All
antigens and four assay controls were immobilized on col-
our coded magnetic beads (MagPlex, Luminex Corp.) using
COOH–NH2 chemistry. The controls consisted of His6ABP
(control of binding to protein tag), buffer (control of bind-
ing to bead particles), rabbit anti human IgG (Jackson, 309-
005-082) (sample loading control), and Epstein Barr nuclear
antigen 1 (EBNA1, abcam, ab138345) (high reactivity fre-
quency expected).
Autoantibody profiling on bead array
IgG reactivities towards human protein fragments were ana-
lysed by an antigen bead array, as previously described
[6–12]. In short, plasma IgG was captured on antigen coated
beads and detected by fluorescent anti-hIgG in a high
throughput format. Individual samples from S3WP visits
1–4 were randomized over six 96-wells plates. Individual
samples from the DHR visits 1–5 were also randomized into
six 96-well plates. Each cohort was analysed at separate time
points. At each analysis day, the samples were thawed in the
fridge, diluted 1:250 in buffer 1 (3% BSA and 5% milk in
PBS supplemented with 0.1% Tween-20 and 160 mg/ml
His6ABP tag) and a sample pool was distributed in tripli-
cates together with one blank well per randomized plate.
Before incubation with the antigen bead array, all samples
were incubated for one hour at room temperature in order
for the His6ABP in the buffer to pre-block any potential
antibodies toward the albumin binding protein domain in
the tag. Subsequently, the plasma samples were incubated
with the antigen bead array for two hours at room tempera-
ture. Goat fab fragments anti human IgG Fc, labeled with
R-phycoerythrin (R-PE, Invitrogen, H10104), were thereafter
added to enable a read out using FlexMap 3D (Luminex
Corp.). For each cohort, the analyses were performed in two
sets of 384-well plates and the read-out was performed sim-
ultaneously on two FlexMap3D instruments. The read out
consisted of the median fluorescent intensity (MFI) and
count of number of beads for each antigen (bead ID) in
each sample.
Data analysis for bead array data
All data analysis was performed using R [14]. Quality con-
trol was performed to exclude antigens and samples not
reaching technical criteria, such as sufficient bead count and
high signal from the anti-hIgG bead. A total of 859 unique
samples were included in the analysis. Continuous median
fluorescent intensity units (MFI) of 20–60,000 were trans-
formed into scored data (17 discrete bins) by the following
algorithm: fMADþmedian (MAD¼median absolute
deviation), where f represented different factors between 0
and 70. The data was also transformed into binary data
using a stringent cut-off of 50MAD above the sample
specific median. Fisher’s exact test was applied on the binary
data to test for reactivity associations regarding the dicho-
tomized sample groups sex (female or male), age (under 40
years or over 60 years), BMI (lower or upper quantile per
cohort), smoking status (never or more than 10 years), alco-
hol intake (less than twice per month or more than once
per week), and self-experienced general health (OK/good or
excellent). Multiple testing correction using the FDR-
approach was applied.
Autoantibody profiling on high density planar
antigen array
High density protein fragment arrays were generated as pre-
viously described [6]. The array consists of 28,000 spots rep-
resenting 14,000 unique protein coding genes by 23,000
different protein fragments produced within the Human
Protein Atlas project as described above. Four individual
samples were selected based on results from the bead array,
and analysed twice on the high-density arrays. Samples were
diluted 1:100 in buffer 1. The samples were incubated in
buffer 1 for 30minutes, and then transferred to the arrays.
The samples were incubated on the arrays for one hour at
room temperature without shaking. After washing in 0.01%
PBS-Tween20, the slides were incubated with chicken anti-
His6ABP (produced within The Human Protein Atlas
Project) for one hour at room temperature on shaker. After
washing, goat anti-human IgG (Hþ L) conjugated with
Alexa 647 (Life Technology, A-21445) with dilution 1:15,000
and goat anti-chicken IgY Alexa 555 (Invitrogen, A-21437)
with dilution 1:15,000 were used following one hour incuba-
tion at room temperature and shaking. After washing, the
slides were scanned using a microarray scanner (Agilent
G2505C, Agilent Technologies Inc.) at a resolution of 10
mm. The images from the scanner were analysed using
GenePix Pro 5.1 image analysis program.
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Data analysis for the planar array
The planar array data werefiltered to remove spots that
were less than 30 pixels in size or flagged during image ana-
lysis. For replicate spots, the mean was calculated if the
coefficient of variation was below 20%, otherwise the spot
with highest spotting control signal was used. Following fil-
tration, the data was transformed per sample to the number
of median absolute deviations (MADs) from the sample
median. Signals were classified as reactive based on a strin-
gent cut-off of 100  MAD of the sample specific base-
line binding.
Results
We have applied an antigen array-based approach to charac-
terize autoantibody repertoires in 859 plasma samples. The
samples were from 193 healthy individuals from two inde-
pendent longitudinal cohorts and have been profiled
towards 204 different proteins with potential associations
with autoimmune disorders. Four samples were subse-
quently analysed also on a high-density array comprising
23,000 protein fragments representing 14,000 protein cod-
ing genes.
Two independent initiatives to profile healthy individuals
were started in October 2015 including longitudinal sam-
plings and monitoring (Figure 1(A)). Both studies set out to
explore the molecular signatures of healthy individuals. The
Swedish SCAPIS SciLifeLab Wellness Profiling (S3WP) pro-
ject enrolled 101 healthy participants of 50–65 years of age.
During one year, the subjects were sampled and answered
questionnaires at four time points. Meanwhile, the Finnish
Digital Health Revolution (DHR) study, conducted at FIMM
research center, enrolled 107 healthy participants of 25–59
years of age, for five samplings and questionnaires during a
period of 16 months. Examples of clear noted differences
between the cohorts are the age span (Figure 1(B)) and the
reported exercise level (Supplementary Table 1). In total,
samples from 193 subjects fulfilled the initial quality criteria
for the arrays. With 4–5 longitudinal samples per subject, a
total of 859 samples were analysed.
In order to characterize the distribution of normally
occurring autoantibody repertoires in relation to disease
associated autoantibody reactivity, we selected 204 proteins
for this study, all with established or speculated associations
with autoimmune disorders (Supplementary Table 2).
Three-hundred and thirty-five protein fragments from the
Human Protein Atlas were selected to represent the 204
proteins and were coupled to colour coded beads and used
to detect the presence of autoreactive IgGs in the subjects’
plasma. The resulting autoantibody profiles demonstrated
that the binding of human IgGs to these human antigens
were person-specific regarding both the number of antigens
and towards which antigens an individual displayed reactiv-
ity. When applying a sample specific scoring algorithm, the
intensity peaks were transformed into reactivity scores (0.
0–1.6). Using a stringent cut-off to classify reactivity, every
binding event with a score of at least 1.2, which corresponds
to a signal greater than 50 times the median absolute devi-
ation (MAD) above the sample specific background, was
classified as reactive. This analytical approach enabled a
graphical display of each autoantibody signature as a bar-
code (Figure 2(A)). The individual autoantibody binding
profile was for most subjects maintained identical across the
four or five samples taken over one year. The personal anti-
body profiles were specific enough to correctly group every
sample from the subjects’ four or five visits together in
unsupervised clustering algorithms, such as the two-dimen-
sional maps based on t-distributed stochastic neighbour
embedding, t-SNE [15] (Figure 2(B)).
Some changes in the autoantibody barcode were observed
over time. The binary definition of reactivity resulted in 170
subjects whose binding towards antigens were classified as
reactive in one sample and unreactive in another (75 in
S3WP and 95 in DHR). However, when a stricter definition
of autoantibody change was applied (Change > 50  MAD,
and reactive in at least 2 samples), six S3WP and nine DHR
subjects displayed antigen binding that occurred during the
study. With this strict definition of reactivity change, no
autoantibody reactivity was lost in any subject during the
timespan of the study. No associated deviations in neither
the clinical data nor the lifestyle questionnaires were found
for these subjects at the time points of the reactivity occur-
rences. Two subjects with occurring autoantibody reactiv-
ities within the timespan of the study are highlighted in
Figure 4(E,F).
Across all studied subjects, the two investigated cohorts
display almost an identical distribution of the total number
of reactivities per subject (Figure 3(A)). On average across
all visits, S3WP subjects’ plasma IgG bound 0–16 antigens,
with a mean and median of six antigens, while DHR sub-
jects bound to 1–15 antigens, with a mean and median of
six as well. The average number of reactivities per subject
did not correlate with the age of the participants (Figure
3(B)), and no significant difference was observed when com-
paring the number of reactivities between the youngest
Figure 1. Two independent approaches for longitudinal sampling of healthy
individuals, DHR in Finland and S3WP in Sweden, display differences in sam-
pling strategy (A) as well as age span (B). Top dots correspond to the dates of
the five visits of DHR-subjects and bottom dots correspond to the dates of the
four visits of S3WP-subjects.
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subjects (<40 years, N¼ 42) and the oldest subjects (>60
years, N = 22), see Supplementary Figure 1. No significant
difference was related to sex (Figure 3(B); Supplementary
Figure 1). Furthermore, none of the explored individual
data (e.g. smoking, alcohol intake, self-experienced general
health or BMI), were here found to be associated to differ-
ences in total number of reactivities at visit 1
(Supplementary Figure 1). Single antigen reactivities were in
some instances associated to individual data, when compar-
ing reactivity frequencies in groups by Fisher’s exact test
(Supplementary Figure 2), but with a number of reactive
subjects so low that the results were regarded as anecdotal
and none were significant after multiple testing correction.
The two subjects from each cohort with the highest num-
ber of reactivities displayed IgG binding towards 16 and 15
antigens, respectively, and will be referred to as S3WP-high
and DHR-high (Figure 4(A,B)). The subjects with the lowest
number of reactivities, S3WP-low and DHR-low (Figure
4(C,D)), displayed reactivity towards none and one antigen,
respectively. To investigate how representative the selected
204 target proteins were for the global autoantibody reper-
toire, these four subjects were selected for IgG-analysis on a
high-density antigen array. An array consisting of 23,000
unique protein fragments, representing 14,000 human pro-
tein coding genes, was applied to represent an unbiased rep-
resentation of antigens. As shown in Figure 5, all four
subjects displayed binding towards 25–62 proteins on this
array, when applying a stringent cut-off of 100  MAD
above the sample specific background. Interestingly, out of
the classified reactivities, IgG binding towards six antigens
were in common between two individuals each (Figure
5(E)), again highlighting the strong individual variation of
autoantibody binding.
On average in these four individuals, there was binding
towards 40 proteins out of 14,000 proteins represented on
the array, which equals to a binding frequency of roughly
3& of the investigated proteins. On the pre-selected array,
consisting of antigens mentioned in the context of auto-
immune disorders, binding was observed to in average six
antigens per subject, which equals a binding frequency of
roughly 3% of the proteins, thus a 10-fold higher frequency
in comparison to the high-density approach. It can be noted
that the number of classified reactivities depend on the
stringency and the algorithm used to set a threshold for
reactivity, which in turn is dependent on the sample and
array format specific background of IgG binding.
The applied antigens were recombinant protein frag-
ments, representing unique parts of human proteins, span-
ning in average 80 amino acids and expressed in E. coli.
Depending on the average number of subjects over all visits,
that displayed IgG-reactivity towards each antigen, the anti-
gens were classified as: unreactive (N = 0 subjects),
Figure 2. (A) Autoantibody profiles displayed as person specific barcodes show the individuality and stability over time of autoantibody repertoires. (B) The per-
sonal autoantibody signature causes the subject’s samples from four or five visits to cluster together when applying a dimensionality reduction of the two datasets
combined, using data transformed into 17 discrete reactivity scores.
Figure 3. (A) The two independent cohorts reveal almost identical distribution
of average number of reactivities per subject across the 335 antigens. (B) No
correlation was found between age and sex with the average number of
reactivities.
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stochastically reactive (N = 1–2 subjects), group reactive (N
= 3–10 subjects) or highly reactive (N > 10 subjects). The
distribution of the number of antigens classified into these
four groups was almost identical between the two cohorts,
here shown for samples from visit 1 (Figure 6). Ten highly
reactive antigens in S3WP were also highly reactive in DHR.
The additional three highly reactive antigens in DHR were
classified as group reactive in S3WP. The identities of the
80 and 82 antigens that were stochastically reactive in S3WP
and DHR, respectively, were divergent in the cohorts. Out
of the 80 antigens that were stochastically reactive in S3WP
subjects, 33 were also stochastically reactive in DHR,
whereas 34 were unreactive and 13 were group reactive. No
correlation was found between the degree of IgG reactivity
measured here and antigen size nor the respective suggested
disease association (data not shown).
The antigens with a high reactivity frequency in each
cohort (reactive in more than 10 subjects per cohort)
were denoted highly reactive antigens and are collected in
Table 1. As shown in Figure 7(A), the highly reactive anti-
gens bind IgG from a range of different subjects. The two
most frequently reactive antigens were ZNF688 and
ARFGAP1. ZNF688 captured IgG from 58 S3WP and 71
DHR subjects, respectively (Figure 7(B)), while ARFGAP
bound IgG from 36 S3WP and 46 DHR subjects, respect-
ively. TRIM21 (also known as SSA or Ro52), an autoantigen
related to Sj€ogren syndrome but also an Fc-receptor binding
protein, shows binding in 10 S3WP and 15 DHR subjects
respectively (Figure 7(C)). KCNJ10 (also known as KIR4.1)
which has been suggested to be associated with multiple
sclerosis, was here bound by IgG in 10 S3WP and 14 DHR
subjects (Figure 7(D)).
Notably, the highly reactive antigens were re-cultivated
from glycerol stocks, purified and analysed, all in triplicates,
to ensure that the binding patterns were related to the
human amino acid sequence represented by the fragment
and not impurities from the production. All highly reactive
antigens were equally reactive in three separate batches of
new produced antigen fragments (data not shown).
Discussion
The profiling of the autoreactive IgG antibody repertoire in
193 healthy individuals enabled us to demonstrate the
Figure 4. Autoantibody binding towards the selected set of 335 human antigens is person specific and stable over repeated sampling over one year. Shown here
are the subjects with the highest number of reactivities (A, B), the subjects with the lowest number of reactivities (C, D), and exemplified subjects with reactivities
occuring during the timespan of each study (E, F). Antigens that are classified as reactive at any visit are interconnected by dashed lines.
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existence of individual specific autoantibody profiles that are
maintained over one year’s time. The overall amount of
detectable self-reactive IgGs to this selected set of proteins
was here, in two independent data sets (S3WP and DHR),
not influenced by neither sex nor age. Furthermore, our
results demonstrate that the plasma autoantibody profiles
represent a unique barcode that could be referred to as an
auto-immuno-fingerprint [3].
The biological causes and consequences of the detected
autoantibody reactivity in healthy individuals are yet to be
fully understood. It has been suggested that the variety of
plasma antibodies that could react to self and non-self-anti-
gens regardless of external stimuli are essential components
of self-defense in health and disease [1]. Natural autoanti-
bodies are generally found in the blood and have been
described as comprising two types of antibodies: i) antigen-
induced antibodies with high specificity, and ii) genetically
determined antibodies with rather broad specificities [16].
Specific autoantibodies detected in serum might be associ-
ated to autoreactive diseases or might be merely part of a
naturally occurring stochastic repertoire. There are reports
of pre-symptomatic patients displaying serum autoantibod-
ies up to 20 years prior onset of an autoimmune disease, for
example, anti-TRIM21 reactivity related to Sj€ogren syn-
drome [17] and anti-citrullinated-peptide antibodies
(ACPA) related to rheumatoid arthritis [18]. Several studies
have shown that healthy individuals have detectable levels of
serum autoantibodies which suggests that autoantibody
positivity is not necessarily disease associated [19–29]. It
remains to be seen if any of the individuals we have investi-
gated herein develop autoimmune diseases.
As for any immunoassay, we observed a continuous gra-
dient from no or low signal intensity to high signal
Figure 5. IgG reactivity towards a high density human protein array for visit 1 samples for the four subjects with the highest (A and C) and lowest (B and D) num-
ber of reactivities in the targeted array. (E) These four individuals were identified to display approximately similar numbers of reactivities on the high density array
when applying a stringent cut-off for reactivity.
Figure 6. Classification of target protein fragments based on data from the
S3WP individuals and the DHR individuals. In each cohort, about half of the
analysed protein fragments were unreactive. Ten antigens were identified to be
highly reactive in both cohorts, whereas three antigens were highly reactive in
DHR and group reactive in S3WP.
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intensity. Clearly, low intensity signals may reflect other bio-
chemical properties of the sample than self-reactive immu-
noglobulins. We therefore applied a classification based on a
stringent sample specific cut-off, to ensure that the defined
reactivities were as reliable as possible. The availability
herein of repeated samples from the same individuals, with
a technical and biological robustness of the measured pro-
files, strengthened our reliability of the algorithm.
Approaches on reactivity classification that are based on the
hypothesis that a majority of individuals included in the
control group should not display reactivity is often seen.
This hypothesis is herein challenged by the identification of
antigens with a high reactivity frequency in the population.
Since array-based assays have the opportunity to include
hundreds or even thousands of antigens, we here decided to
make use of an algorithm defining a cut-off based on the
sample specific binding profile towards all antigens. Our
hypothesis is that every individual should be unreactive
towards a majority of the investigated antigens. Using this
approach, a subset of antigens was here defined as highly
reactive, meaning that more than 10% of the studied indi-
viduals had IgG-binding classified as reactive.
For high-reactive antigens, we plan to map the IgG bind-
ing to smaller regions, or autoantibody epitopes. This would
provide us with the possibility to investigate whether these
regions of self-antigens towards which a high proportion of
individuals display IgG binding represent or contain
sequence or structural similarities to antigens found in spe-
cific infectious agents, such as viral or bacterial surface pro-
teins. These approaches are currently pursued in further
characterization of the high-reactive antigens we identified
here. The two most reactive antigens in this collection were
ZNF688 and ARFGAP1. Previous studies in our research
group have demonstrated that patients with certain auto-
immune disorders have plasma IgG with very high binding
intensities to these antigens [11], although a large propor-
tion of control subjects also display binding. The high fre-
quencies of reactive individuals to disease related antigens,
such as TRIM21 (also known as SSA or Ro52, related to
Sj€ogren syndrome and SLE), and KCNJ10 (also known as
KIR4.1, suggested to be related to multiple sclerosis [29]),
are here highlighted as examples of the importance of
profiling healthy autoantibody repertoires when studying
autoimmune reactivities.
Here, we present autoantibody repertoires of a large
number of well-characterised healthy individuals over time.
This data highlights the need of personalized baselines as
phrased within precision medicine. In a recent review,
Burbelo et al. suggested the possibility to perform routine
autoantibody mapping using a protein panel that could con-
sist of large numbers of diverse antigens including viral
antigens, bacterial, yeast, and fungal proteins, as well as can-
cer-related antigens, self-antigens and known autoimmune
targets [30]. In our approach we aimed at detecting the
prevalence of autoantibodies of the IgG type, which are the
most abundant immunoglobulins. Some reports claim that
autoreactive IgGs act mainly as pathogenic autoantibodies,
whilst IgM type autoantibodies are referred to as naturally
occurring autoantibodies in healthy individuals [1,31,32].
Nevertheless, to our knowledge, there are no major screen-
ing efforts that have been performed to date in order to
investigate natural occurring IgM type autoantibodies in
healthy individuals over a specific period of time.
When observing IgG reactivities over time, it has been
postulated earlier [3,33–35], as well as presented herein, that
the overall profile is maintained stable across months to a
few years in time. The limited set of individuals and the
(immunologically) short time span of our study limit the
conclusions on age related autoantibody prevalence. There
are, as far as we are aware, no longitudinal studies investi-
gating long-term stability over decades. It has been sug-
gested that the IgG repertoires of healthy individuals are
achieved early in life and then remain stable, while reactiv-
ities towards bacterial antigens may change depending on
age [36]. Previous studies have reported increased positivity
associated to age when measuring anti-nuclear antibodies
(ANA) in almost 30,000 Chinese individuals [27], indicating
an accumulation of B-cell responses, whereas other studies
reported the opposite finding [37]. Both of these studies
reported an increased frequency of ANA positivity in
Table 1. Highly reactive antigens.









ZNF688 Zinc finger protein 688 P0C7X2 Sarcoidosis 58 (60%) 71 (74%)
ARFGAP1 ADP ribosylation factor GTPase
activating protein 1
Q8N6T3 Sarcoidosis 36 (37%) 46 (48%)
PRPH Peripherin P41219 Diabetes type 1 18 (18%) 26 (27%)
TNNT2 Troponin T2, cardiac type P45379 Autoimmune hepatitis 18 (19%) 23 (24%)
MYH10 Myosin heavy chain 10 P35580 Myasthenia gravis 11 (11%) 20 (21%)
ICA1 Islet cell autoantigen 1 Q05084 Diabetes type 1 21 (22%) 18 (18%)
CENPF Centromere protein F P49454 Systemic sclerosis 24 (25%) 17 (17%)
DST Dystonin Q03001 Bollous pemphigoid 8 (8%) 16 (16%)
TRIM21 Tripartite motif containing 21 P19474 Sjogrens Syndrome 10 (11%) 15 (16%)
KCNJ10 Potassium voltage-gated channel
subfamily J member 10
P78508 Multiple sclerosis 10 (11%) 14 (14%)
FTCD Formimidoyltransferase
cyclodeaminase
O95954 Autoimmune hepatitis 14 (14%) 13 (13%)
ANXA2 Annexin A2 P07355 Antiphospholipid
syndrome
13 (13%) 13 (13%)
NCOA2 Nuclear receptor coactivator 2 Q15596 Sarcoidosis 9 (9%) 12 (13%)
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females compared to males, which is in agreement with the
higher prevalence of autoimmune disorders in females and
the relation of ANA-positivity and certain autoimmune dis-
orders. A protein array analysis investigating IgG binding
towards almost 10,000 proteins claims that the number of
reactivities was significantly influenced by age and sex in
healthy individuals, using an inclusive cut-off of reactivity
[35]. In our presented work, based on a subjective yet strin-
gent classification of reactivity, we did not observe any
impact of age nor sex on the antibody profiles. However,
the occurring reactivities that we observe are acquired and
maintained in subsequent samples, and no reactivity appears
to be lost over the study time. If this pattern would extrapo-
late over time, there are reasons to hypothesize that the self-
reactive IgG repertoire is accumulated with age, although in
such individual pace that the trend is only observed in
population studies of certain size.
Conclusion
In conclusion, healthy individuals display autoantibody
binding to self-antigens, which is individual and stable over
time. This naturally occurring autoantibody reactivity needs
to be taken into account when investigating association of
autoantigens with diseases. Discussions on algorithms for
selecting un-biased and stringent cut-offs for reactivity are
important for the autoimmunity profiling community. With
new, improved technologies emerging, broader and deeper
autoantibody profiling efforts are possible, which will pro-
vide a data-driven basis for further understanding of
Figure 7. (A) Autoantibody reactivities of 193 individuals (visit 1) towards 13 antigens identified as highly reactive. (B) ZNF688 was discovered as the antigen with
IgG binding in the most samples. (C) Reactivity plots for IgG binding to TRIM21, also known as SSA or Ro52. (D) Reactivity plots for IgG-binding to KCNJ10, also
known as KIR4.1. The binding fluorescence intensity is plotted for each individual at each time point for the S3WP subjects and the DHR subjects. Data points
which were classified as reactive by the stringent cut-off are interconnected by a dashed line connecting data points from the same individual.
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autoantibodies in health and disease. In this study, we have
generated and presented a longitudinal perspective on the
distribution of the self-reactive IgG repertoire in healthy
individuals.
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